Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy (Q38361603)

2 September 2017

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy (English)

1 reference

2 September 2017

1 reference

1

1 reference

2 September 2017

12

1 reference

2 September 2017

Kreil S

2

1 reference

2 September 2017

Corbin AS

3

1 reference

2 September 2017

La Rosée P

4

1 reference

2 September 2017

Müller MC

5

1 reference

2 September 2017

Lahaye T

6

1 reference

2 September 2017

Hanfstein B

7

1 reference

2 September 2017

Schoch C

8

1 reference

2 September 2017

Cross NC

9

1 reference

2 September 2017

Berger U

10

1 reference

2 September 2017

Gschaidmeier H

11

1 reference

2 September 2017

Hehlmann R

13

1 reference

2 September 2017

1 November 2002

1 reference

2 September 2017

1 reference

2 September 2017

16

1 reference

2 September 2017

11

1 reference

2 September 2017

2190-2196

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402741

2 September 2017

0 references

cites work

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Minimal Residual Disease after Bone Marrow Transplant for Chronic Myeloid Leukaemia Detected by the Polymerase Chain Reaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

The P-loop--a common motif in ATP- and GTP-binding proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Cytogenetics of chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402741

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402741

1 reference

Dimensions Publication ID

2 September 2017

0 references

1 reference